Genetically engineered vaccine strain
AssigneeVirogenetics Corporation
InventorsEnzo Paoletti, Marion E. Perkus
Life of this patent
Estimating the term…
Abstract
What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
Claims8
A recombinant vaccinia virus wherein regions C7L-K1L, J2R, B13R+B14R, A26L, A56R and I4I have been deleted therefrom.
A recombinant vaccinia virus wherein the open reading frames:
- for the thymidine kinase gene, the hemorrhagic region, the A type inclusion body region, the hemagglutinin gene, the host range gene region, and the large subunit, ribonucleotide reductase have been deleted therefrom.
Dependencies are inferred from the claim text.